Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Papadopoulos (Oxford, United Kingdom), S. Zannetos (Nicosia, Cyprus), R. Hoyles (Oxford, United Kingdom). Factors influencing Idiopathic Pulmonary Fibrosis (IPF) anti-fibrotic decisions in a single UK centre; patient and physician perspectives. 4778

Member's Comments

No comment yet.

Related content which might interest you: What proportion of patients with Idiopathic Pulmonary Fibrosis fall outside UK prescribing criteria for anti-fibrotic treatment? A UK specialist centre review. Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia Year: 2019 Lessons learned when recruiting for an early Idiopathic Pulmonary Fibrosis (IPF) palliative care intervention Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments Year: 2018 The European IPF Registry: Addressing challenges and characteristics of patients with Idiopathic Pulmonary Fibrosis Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries Year: 2018 Impact of an interstitial lung diseases Nurse on the compliance to anti-fibrotic drugs in patients with Idiopathic Pulmonary Fibrosis. Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF) Year: 2018 Management-related costs of Idiopathic Pulmonary Fibrosis (IPF) in Belgium Source: Virtual Congress 2020 – How do different treatment strategies translate into costs Year: 2020 IPF Care, a support program for patients with idiopathic pulmonary fibrosis in the UK Source: International Congress 2015 – Latest insights into chronic care Year: 2015 Clinical characteristics of patients with Idiopathic pulmonary fibrosis in a tertiary care center of a developing country Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016 Pirfenidone in idiopathic pulmonary fibrosis (IPF): Early Spanish experience with the European Named patient program (NPP) Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 Clinical burden of idiopathic pulmonary fibrosis (IPF): physician and patient perception Source: Virtual Congress 2020 – Clinical aspects of idiopathic pulmonary fibrosis Year: 2020 A supportive care decision aid tool for idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 The value of a specialist nurse-lead interstitial lung disease clinic, patients’ views Source: International Congress 2015 – Kaleidoscope of nursing research Year: 2015 The development of a measure to better understand patient experiences with pirfenidone and nintedanib for the treatment of idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 Do physicians in primary health care recognize pulmonary fibrosis? Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Inspiration: An assistance program for idiopathic pulmonary fibrosis patients on pirfenidone Source: International Congress 2014 – Respiratory symptoms in primary care populations Year: 2014 Pirfenidone in idiopathic pulmonary fibrosis (IPF): Early single centre Irish experience Source: Annual Congress 2012 - Diffuse parenchymal lung disease III Year: 2012 Clinical outcomes of patients with idiopathic pulmonary fibrosis in clinical practice: Follow-up results of the INSIGHTS-IPF registry Source: International Congress 2015 – IPF: clinical aspects II Year: 2015 Predicting life expectancy for pirfenidone and best supportive care (BSC) in idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF treatment II Year: 2016 Inspiration plus: baseline characteristics of the canadian registry for IPF patients on pirfenidone Source: International Congress 2016 – Orphan diseases II Year: 2016 Assessing the effectiveness of pirfenidone in changing the natural course of idiopathic pulmonary fibrosis: the data from European IPF Registry (eurIPFreg). Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 The burden of Idiopathic Pulmonary Fibrosis (IPF): a multimodal study of prevalence, healthcare utilization and survival Source: Virtual Congress 2020 – Clinical aspects of idiopathic pulmonary fibrosis Year: 2020